<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04006535</url>
  </required_header>
  <id_info>
    <org_study_id>2019-A00188-49</org_study_id>
    <nct_id>NCT04006535</nct_id>
  </id_info>
  <brief_title>Whole Exome Sequencing of Familial and Pediatric Forms of Vasculitis</brief_title>
  <acronym>FAMILYVASC</acronym>
  <official_title>Identification of Susceptibility Loci and Genes for Systemic Vasculitis Risk, by Analyzing Whole Exome Sequencing of Familial and Pediatric Forms of Vasculitis (FAMILYVASC Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Benjamin Terrier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>French Vasculitis Study Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The FAMILYVASC study is a prospective observational study which will aim to identify
      susceptibility loci and genes for systemic vasculitis risk in patients with familial or
      pediatric forms of vasculitis. Genetic analysis based on whole exome sequencing will be
      carried out through salivary DNA.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2029</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2029</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Family-Based</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of susceptibility loci and genes</measure>
    <time_frame>At the moment of enrollment</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Vasculitis</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>genetic analysis</intervention_name>
    <description>Saliva sample collection for genetic analysis</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Saliva samples will be collected for genetic analysis and identification of susceptibility
      loci and genes for the risk of vasculitis.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult and childhood patients (no age limit) with familial and pediatric forms of vasculitis
        as defined in Chapel Hill's international nomenclature in its revised 2012 version.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria for subjects with vasculitis

          -  Children and adults

          -  Patients with vasculitis, as defined in the Chapel Hill International Classification
             in its revised version of 2012

          -  Patient information and signed informed consent

          -  Pregnant and breastfeeding women can be included in the study

        Inclusion criteria for healthy subjects

          -  Children and adults

          -  Do not have vasculitis, as defined in the Chapel Hill International Classification in
             its revised version of 2012, or relatives on the 1st; 2nd; 3rd or 4th degree of a
             patient with vasculitis

          -  Patient information and signed informed consent

          -  Pregnant and breastfeeding women can be included in the study

        Exclusion criteria:

          -  Refusal of consent or inability to obtain consent

          -  Dementia or unauthorized patient, for psychiatric or intellectual failure reasons, to
             receive information about the protocol and to give informed consent.

          -  Uncooperative patient, or any pathology that could make the patient potentially
             non-compliant to the study procedures, and patients interned for regulatory or legal
             reasons.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin Terrier, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>French Vasculitis Study Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benjamin Terrier, MD, PhD</last_name>
    <phone>+33 1 58 41 14 61</phone>
    <email>benjamin.terrier@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hicham Kardaoui, MSc</last_name>
    <phone>+33 1 58 41 16 46</phone>
    <email>hicham.kardaoui@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HÃ´pital Cochin - Department of Internal Medicine</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Terrier, MD, PhD</last_name>
      <phone>+ 01 58 41 14 61</phone>
      <email>benjamin.terrier@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.vascularites.org</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 1, 2019</study_first_submitted>
  <study_first_submitted_qc>July 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>July 3, 2019</last_update_submitted>
  <last_update_submitted_qc>July 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>French Vasculitis Study Group</investigator_affiliation>
    <investigator_full_name>Benjamin Terrier</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Vasculitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasculitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

